European Primary Care Cardiovascular Society

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France
Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

Lower extremity artery disease: a neglected major CV disease

Dr. Rafel Ramos - Girona, Spain

EPCCS 2018 An impression of the presentation of dr. Rafel Ramos on diagnosis and clinical management of peripheral artery disease in primary care, given during the Annual EPCCS CV Summit.

International Heart Rhythm Societies give advice on limiting cognitive decline in AF

Mar. 27, 2018 - news

Four Heart Rhythm Societies have composed a consensus statement on how to prevent, assess and treat cognitive decline in atrial fibrillation and other arrhythmias.

New EHRA Practical Guide on the use of NOACs for stroke prevention in AF

Mar. 21, 2018 - news

The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.

Shift of statin eligibility to more subjects at intermediate CV risk with new criteria

Mar. 21, 2018 - Cesena FHY, et al. - Am J Cardiol 2018

Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.

Central adiposity is stronger associated with risk of MI than general adiposity

Mar. 21, 2018 - Peters SAE, et al. - J Am Heart Assoc. 2018

In a large, prospective, population-based cohort, the waist-to-hip ratio was more strongly associated with the risk of MI compared with BMI, especially in women.

Safety profile of NOAC for SPAF confirmed in large prospective real-world registry

Mar. 20, 2018 - news

New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.

Association of physical activity with less CVD mortality in CHD patients

Mar. 19, 2018 - Moholdt T, et al. - J Am Coll Cardiol 2018

Maintaining or increasing physical activity was associated with substantial reductions in CVD mortality risk, in a large cohort of patients with angina pectoris or myocardial infarction.

Second EPCCS Council Meeting: expanding the impact for European GPs

Mar. 15, 2018 - news
Already at the second Council meeting, we shift gears from making plans to taking action and bringing the support of the European Primary Cardiovascular Care Community to a higher level.

EPCCS Council Already at the second Council meeting, we shift gears from making plans to taking action and bringing the support of the European Primary Cardiovascular Care Community to a higher level.

MACE safely reduced by another PCSK9 inhibitor in long term outcomes trial in high-risk patients

Presented at ACC.18 by Ph. Gabriel Steg (Paris, France)

Mar. 13, 2018 - news

ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.

Rate of AF diagnosis improves by self-applied ECG patch

Presented at ACC.18 by Steven Steinhubl (La Jolla, CA, USA)

Mar. 13, 2018 - news

ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.

In post-MI patients with low LVEF, wearable cardioverter-defibrillator reduces total mortality

Presented at ACC.18 by Jeffrey Olgin (San Francisco, CA, USA)

Mar. 13, 2018 - news

ACC 2018 In post-MI patients with a low LVEF, WCD reduced total mortality in the immediate post-MI period (<90 days), but not sudden cardiac death.